Skip to main content
Terug
EXETF logo

Extendicare Inc.

Datakwaliteit: 100%
EXETF
OTC Healthcare Medical - Care Facilities
€ 18,61
▲ € 0,08 (0,43%)
Marktkapitalisatie: 1,76B
Dagbereik
€ 18,61 € 18,61
52-Weeksbereik
€ 8,62 € 20,78
Volume
200
50D / 200D Gem.
€ 17,91 / € 13,07
Vorige Slotkoers
€ 18,53

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 18,2 0,4
P/B 4,7 2,9
ROE % 38,8 3,7
Net Margin % 5,8 3,8
Rev Growth 5Y % 9,2 10,0
D/E 0,9 0,2

Belangrijkste Punten

Revenue grew 9,19% annually over 5 years — modest growth
Earnings grew 28,41% over the past year
ROE of 38,83% indicates high profitability
Generating 63,35M in free cash flow
PEG of 0,83 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,96%

Groei

Revenue Growth (5Y)
9,19%
Revenue (1Y)13,15%
Earnings (1Y)28,41%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
38,83%
ROIC14,49%
Net Margin5,82%
Op. Margin8,33%

Veiligheid

Debt / Equity
0,92
Current Ratio1,37
Interest Coverage7,20

Waardering

P/E Ratio
18,20
P/B Ratio4,71
EV/EBITDA12,67
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13,15% Revenue Growth (3Y) 12,75%
Earnings Growth (1Y) 28,41% Earnings Growth (3Y) 68,58%
Revenue Growth (5Y) 9,19% Earnings Growth (5Y) 70,22%
Profitability
Revenue (TTM) 1,66B Net Income (TTM) 96,58M
ROE 38,83% ROA 9,06%
Gross Margin 12,02% Operating Margin 8,33%
Net Margin 5,82% Free Cash Flow (TTM) 63,35M
ROIC 14,49% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,92 Current Ratio 1,37
Interest Coverage 7,20 Dividend Yield 0,02%
Valuation
P/E Ratio 18,20 P/B Ratio 4,71
P/S Ratio 1,06 PEG Ratio 0,83
EV/EBITDA 12,67 Dividend Yield 0,02%
Market Cap 1,76B Enterprise Value 1,75B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,66B 1,47B 1,30B 1,22B 1,17B
Net Income 96,58M 75,21M 33,98M 69,55M 11,50M
EPS (Diluted) 1,11 0,86 0,40 -0,05 0,11
Gross Profit 199,43M 1,47B 167,62M 76,83M 115,61M
Operating Income 138,25M 111,21M 111,79M 20,99M 63,18M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,07B 719,79M 672,73M 781,58M 900,32M
Total Liabilities 692,58M 595,44M 584,81M 680,88M 798,40M
Shareholders' Equity 373,07M 124,35M 87,92M 100,70M 101,92M
Total Debt 342,65M 292,49M 334,52M 383,97M 536,85M
Cash & Equivalents 348,90M 121,85M 75,18M 167,28M 104,63M
Current Assets 451,57M 243,70M 187,14M 258,04M 224,92M
Current Liabilities 329,91M 292,88M 226,39M 274,99M 281,91M

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#205 of 326
45
Custom Balanced Risk
#106 of 148
41
Custom Lower Risk
#131 of 136
25

Recente Activiteit

Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026